KR102869852B1 - 크론병을 치료하는 방법에 사용하기 위한 미리키주맙 - Google Patents

크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Info

Publication number
KR102869852B1
KR102869852B1 KR1020217034113A KR20217034113A KR102869852B1 KR 102869852 B1 KR102869852 B1 KR 102869852B1 KR 1020217034113 A KR1020217034113 A KR 1020217034113A KR 20217034113 A KR20217034113 A KR 20217034113A KR 102869852 B1 KR102869852 B1 KR 102869852B1
Authority
KR
South Korea
Prior art keywords
mirikizumab
delete delete
weeks
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217034113A
Other languages
English (en)
Korean (ko)
Other versions
KR20210142704A (ko
Inventor
스튜어트 윌리엄 프리드리히
폴 프레드릭 폴락
제이 로렌스 터틀
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Priority to KR1020257033226A priority Critical patent/KR20250153865A/ko
Publication of KR20210142704A publication Critical patent/KR20210142704A/ko
Application granted granted Critical
Publication of KR102869852B1 publication Critical patent/KR102869852B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020217034113A 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙 Active KR102869852B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257033226A KR20250153865A (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836,910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257033226A Division KR20250153865A (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Publications (2)

Publication Number Publication Date
KR20210142704A KR20210142704A (ko) 2021-11-25
KR102869852B1 true KR102869852B1 (ko) 2025-10-14

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217034113A Active KR102869852B1 (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙
KR1020257033226A Pending KR20250153865A (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257033226A Pending KR20250153865A (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Country Status (16)

Country Link
US (1) US20220040299A1 (https=)
EP (1) EP3958897A1 (https=)
JP (3) JP7297930B2 (https=)
KR (2) KR102869852B1 (https=)
CN (2) CN113677366A (https=)
AU (2) AU2020263238C1 (https=)
BR (1) BR112021018930A2 (https=)
EA (1) EA202192532A1 (https=)
IL (2) IL286818B2 (https=)
MA (1) MA55756A (https=)
MX (1) MX2021012848A (https=)
SG (1) SG11202110619XA (https=)
TW (2) TW202515610A (https=)
UA (1) UA128657C2 (https=)
WO (1) WO2020219314A1 (https=)
ZA (1) ZA202108094B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
CA3068673A1 (en) * 2017-07-10 2019-01-17 Rambam Med-Tech Ltd. Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. Ma et al. Expert Opinion on Investigational Drugs. 2018, vol.27, pp.649-660*
C. Ma et al. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs. 2018, vol.27, pp.649-660*
대한민국 공개특허공보 제10-2018-0053395호(2018.05.21.) 1부.*

Also Published As

Publication number Publication date
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
KR20210142704A (ko) 2021-11-25
IL324048A (en) 2025-12-01
MX2021012848A (es) 2021-12-10
JP7761614B2 (ja) 2025-10-28
JP2022530397A (ja) 2022-06-29
AU2020263238A1 (en) 2021-11-04
NZ781127A (en) 2025-06-27
CN119700968A (zh) 2025-03-28
MA55756A (fr) 2022-03-02
ZA202108094B (en) 2025-05-28
IL286818B2 (en) 2026-03-01
AU2020263238B2 (en) 2023-08-17
AU2023265759A1 (en) 2023-12-07
IL286818B1 (en) 2025-11-01
IL286818A (en) 2021-10-31
CA3134587A1 (en) 2020-10-29
SG11202110619XA (en) 2021-11-29
CN113677366A (zh) 2021-11-19
JP7297930B2 (ja) 2023-06-26
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
WO2020219314A1 (en) 2020-10-29
KR20250153865A (ko) 2025-10-27
EP3958897A1 (en) 2022-03-02
UA128657C2 (uk) 2024-09-18
TW202515610A (zh) 2025-04-16
BR112021018930A2 (pt) 2022-01-18
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
AU2020263238C1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
AU2023248103B2 (en) Methods of treating ulcerative colitis
Saunders et al. Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies
Armuzzi et al. Ustekinumab in the management of Crohn’s disease: Expert opinion
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
CA3134587C (en) Mirikizumab for use in a method of treating crohn's disease
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)